MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.44
+0.19
+2.05%
Closed 16:00 09/16 EDT
OPEN
9.50
PREV CLOSE
9.25
HIGH
9.85
LOW
9.42
VOLUME
29.21K
TURNOVER
--
52 WEEK HIGH
14.45
52 WEEK LOW
5.41
MARKET CAP
243.32M
P/E (TTM)
-5.3964
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XENE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XENE News

  • The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris
  • Benzinga.09/10 11:39
  • Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexions Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
  • GlobeNewswire.09/09 21:01
  • Flexion in-licenses pain candidate from Xenon Pharma for up to $128M
  • Seeking Alpha - Article.09/09 20:14
  • Flexion Therapeutics And Xenon Pharmaceuticals Announce Flexion's Acquisition Of An Investigational NaV1.7 Inhibitor For The Treatment Of Post-Operative Pain; Xenon Received $3M Upfront And Is Eligible For Additional Milestones
  • Benzinga.09/09 20:03

More

Industry

Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
-0.15%

Hot Stocks

Name
Price
%Change

About XENE

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
More

Webull offers Xenon Pharmaceuticals Inc (XENE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.